US equities |
NVDA $239.75 ▲+2.48% SPCX $169.78 ▲+6.80% MU $1,061.83 ▼-1.21% TSLA $379.87 ▲+2.50% SNDK $1,700.54 ▼-1.13% MSFT $527.87 ▲+2.00% INTC $116.23 ▼-2.59% META $742.89 ▲+2.03%
FinancialContent

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗
Via Stocktwits
News headline image
Thursday's after hours session: top gainers and losers ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week ↗
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline. 
Via Benzinga
News headline image
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
XOMA Royalty adds milestone and royalty economics associated with two partnered assets 
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang ↗
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts. 
Via Benzinga
News headline image
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
These stocks have an unusual volume in today's session 
Via Chartmill
News headline image
What's going on in today's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024 ↗
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
News headline image
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023 
From LAVA Therapeutics N.V.
Via GlobeNewswire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
< Previous 1 2 3 4 Next >